VERU - Veru Pharma

-

$undefined

N/A

(N/A)

Veru Pharma NasdaqCM:VERU Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Location: 2916 North Miami Avenue, Miami, FL, 33127, United States | Website: https://verupharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

59.92M

Cash

19.62M

Avg Qtr Burn

-7.27M

Short % of Float

11.89%

Insider Ownership

14.19%

Institutional Own.

33.02%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ENTADFI™ (tadalafil and finasteride) Details
Benign prostatic hyperplasia (BPH)

Approved

Update

Enobosarm +/- abemaciclib Details
HER2-expressing cancers, ER+/HER2- breast cancer

Phase 3

Update

Phase 3

Update

Enobosarm +GLP-1 drugs [Ozempic® + Wegovy® + Mounjaro®] Details
Obesity

Big Mover™

Susp. Mover™

Phase 2b

Data readout

VERU-100 Details
Prostate cancer, Cancer

Failed

Discontinued

Failed

Discontinued

Sabizabulin (VERU-111) Details
Castration-resistant prostate cancer

Failed

Discontinued

Sabizabulin (VERU-111) + Enobosarm Details
Triple-negative breast cancer , Cancer

Failed

Discontinued